Skip to main content
XCUR
NASDAQ Life Sciences

Exicure Appoints New CEO and Interim CFO, Filling Key Leadership Vacancies

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$3.81
Mkt Cap
$24.762M
52W Low
$3.101
52W High
$15.91
52W Position info
23% above low
Off High info
76% below high
Rel. Volume
Market data snapshot near publication time

XCUR sits 23% above its 52-week low of $3.101.

Summary

Exicure, Inc. has appointed Jung Soo Kim as its new CEO and President, and Gyuyeob Lee as Interim CFO and Secretary, effectively filling the critical leadership positions that were recently vacated.


Key Events · Executive and Board Changes · XCUR

  • New CEO Appointed

    Jung Soo Kim has been appointed as the Chief Executive Officer and President of Exicure, Inc., effective February 11, 2026.

  • Interim CFO Appointed

    Gyuyeob Lee has been appointed as the Interim Chief Financial Officer and Secretary of the Company, also effective February 11, 2026.

  • Leadership Vacancies Filled

    These appointments resolve the C-suite vacancies that resulted from the resignations of the previous CEO and CFO, which were announced in an 8-K filing on February 10, 2026.

  • Executive Services Agreements

    The services for the new CEO and Interim CFO will be provided to the Company pursuant to executive services agreements with Innocircle Advisors Inc.


Analysis · XCUR · Life Sciences

This 8-K filing addresses the significant leadership vacuum created by the resignations of the previous CEO and CFO, which were disclosed in a prior 8-K on February 10, 2026. The appointment of Jung Soo Kim as CEO and President, and Gyuyeob Lee as Interim CFO and Secretary, provides much-needed stability and direction for the company. For a micro-cap company like Exicure, Inc., having a complete executive team is crucial for operational continuity and investor confidence, especially following recent significant shareholder sales and a clinical trial milestone. The new executives bring experience in corporate strategy, capital markets, and financial management, which could be vital for the company's future.

At the time of this filing, XCUR was trading at $3.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.8M. The 52-week trading range was $3.10 to $15.91. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XCUR - Latest Insights

XCUR
Jul 17, 2026, 4:39 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $1.74 info
Change: +$0.110 (+7%) info
Market Cap: $11.091M info
XCUR
Jul 17, 2026, 1:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $1.67
Real-time Price: $1.74 info
Change: +$0.075 (+5%) info
Market Cap: $11.091M info
XCUR
Jun 30, 2026, 3:03 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $1.74 info
Change: -$0.2616 (-13%) info
Market Cap: $11.091M info
XCUR
Jun 30, 2026, 2:55 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.03
Real-time Price: $1.74 info
Change: -$0.290 (-14%) info
Market Cap: $11.091M info
XCUR
May 29, 2026, 2:09 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $3.16
Real-time Price: $1.74 info
Change: -$1.42 (-45%) info
Market Cap: $11.091M info